292 studies found for:    Open Studies | "Carcinoma, Renal Cell"
Show Display Options
Rank Status Study
21 Recruiting Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: AdGMCAIX-transduced autologous dendritic cells;   Biological: therapeutic autologous dendritic cells;   Other: laboratory biomarker analysis
22 Recruiting Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Gastrinoma;   Glucagonoma;   HER2-negative Breast Cancer;   Insulinoma;   Mucositis;   Oral Complications;   Pancreatic Polypeptide Tumor;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Islet Cell Carcinoma;   Recurrent Renal Cell Cancer;   Somatostatinoma;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Renal Cell Cancer
Intervention: Drug: everolimus
23 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
24 Recruiting Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer
Conditions: Head and Neck Squamous Cell Carcinoma;   Metastatic Renal Cell Cancer;   Recurrent Head and Neck Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Skin Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma
Interventions: Radiation: Radiation Therapy (RT);   Drug: MK-3475
25 Recruiting Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate;   Biological: Trebananib
26 Recruiting Intraoperative Dual-modality Imaging in Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Interventions: Drug: Indium-111-DOTA-Girentuximab-IRDye800CW;   Radiation: SPECT/CT;   Procedure: Intraoperative dual-modality imaging
27 Recruiting Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Condition: Metastatic Renal Cell Cancer
Interventions: Drug: RX-0201;   Drug: Everolimus
28 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
29 Recruiting Tumor Registry of Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
30 Recruiting Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.
Condition: Carcinoma, Renal Cell
Intervention: Radiation: Stereotactic body radiotherapy
31 Recruiting Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Condition: Kidney Cancer
Interventions: Drug: Pazopanib;   Drug: Temsirolimus;   Behavioral: Quality of Life Assessment;   Drug: Benadryl
32 Recruiting Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib
33 Recruiting Kidney Cancer DNA Registry
Condition: Renal Cancer
Interventions: Other: salvia for germline DNA;   Behavioral: the Kidney Cancer Questionnaire;   Behavioral: Family History Questionnaire (when applicable)
34 Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
35 Not yet recruiting REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Intervention: Drug: Iodine (124I) Girentuximab
36 Unknown  Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
Condition: Kidney Cancer
Intervention: Drug: sunitinib malate
37 Recruiting Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Conditions: Renal Cancer;   Chromophobe Renal Cell Carcinoma;   Birt-Hogg-Dube Syndrome
Intervention: Drug: Everolimus
38 Unknown  Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: aldesleukin;   Biological: bevacizumab
39 Recruiting Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method
40 Recruiting Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
Conditions: Genitourinary Cancer;   Kidney Cancer
Interventions: Drug: Sunitinib;   Behavioral: Questionnaire

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years